Personalized fracture care combining patient stratification and targeted immunomodulatory therapy to prevent poor bone healing ‐ The PRECISION study (P16)

• Subject Area: Medical Informatics and Medical Bioinformatics
• Term: since 2021
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 427826188

Annually, there are 160-190 million fractures worldwide, with around 700,000 cases in Germany alone. While most fractures heal completely, our recent data indicate that more than of patients experience delayed or non-healing, necessitating additional interventions. Early identification of high-risk patients is crucial for tailored treatment strategies. CD8+ TEMRA cells serve as promising prognostic biomarkers for predicting healing outcomes. Building on insights from the multicenter BioBone study, we confirmed the value of this biomarker. In our phase I IloBone study, we are evaluating the safety of local pharmacological intervention using Iloprost in patients with proximal humerus fractures. Our subsequent phase II trial, the PRECISION study, integrates prognostic and therapeutic strategies to reduce compromised bone healing in high-risk patients effectively.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 1444: Directed Cellular Self-Organization to Advance Bone Regeneration
• Applicant Institution: shared FU Berlin and HU Berlin through:; Charité - Universitätsmedizin Berlin
• Project Heads: Dr. Sven Geißler; Professor Dr. Tobias Winkler